UX023: Interim Phase II data

Interim data from the open-label, U.S. Phase II UX023T-CL201 trial showed that 6 of 8 patients with TIO or epidermal nevus syndrome receiving subcutaneous KRN23 every 4 weeks

Read the full 288 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE